Front Row Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Front Row Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26K	Hold	18	–	–	﹤0.01%	527
2026 Q1	$978	Hold	18	–	–	﹤0.01%	528
2025 Q4	$1.01K	Hold	18	–	–	﹤0.01%	509
2025 Q3	$867	Sell	18 -9	-33%	-$402	﹤0.01%	511
2025 Q2	$1.1K	Sell	27 -18	-40%	-$724	﹤0.01%	494
2025 Q1	$1.98K	Hold	45	–	–	﹤0.01%	448
2024 Q4	$1.94K	Hold	45	–	–	﹤0.01%	445
2024 Q3	$2K	Hold	45	–	–	﹤0.01%	445
2024 Q2	$1.8K	Hold	45	–	–	﹤0.01%	859
2024 Q1	$1.95K	Hold	45	–	–	﹤0.01%	848
2023 Q4	$1.88K	Hold	45	–	–	﹤0.01%	417
2023 Q3	$1.8K	Hold	45	–	–	﹤0.01%	822
2023 Q2	$2K	Hold	45	–	–	﹤0.01%	831
2023 Q1	$2K	Buy	+45	New	+$1.89K	﹤0.01%	846
2022 Q4	–	Sell	-45	Closed	-$1.87K	–	950
2022 Q3	$2K	Hold	45	–	–	﹤0.01%	844
2022 Q2	$2K	Hold	45	–	–	﹤0.01%	854
2022 Q1	$2K	Buy	45 +1	+2%	+$44	﹤0.01%	883
2021 Q4	$2K	Hold	44	–	–	﹤0.01%	897
2021 Q3	$2K	Hold	44	–	–	﹤0.01%	891
2021 Q2	$2K	Hold	44	–	–	﹤0.01%	894
2021 Q1	$2K	Hold	44	–	–	﹤0.01%	889
2020 Q4	$2K	Hold	44	–	–	﹤0.01%	851
2020 Q3	$2K	Hold	44	–	–	﹤0.01%	849
2020 Q2	$2K	Hold	44	–	–	﹤0.01%	886
2020 Q1	$2K	Hold	44	–	–	﹤0.01%	860
2019 Q4	$2K	Hold	44	–	–	﹤0.01%	819
2019 Q3	$2K	Hold	44	–	–	﹤0.01%	823
2019 Q2	$2K	Hold	44	–	–	﹤0.01%	884
2019 Q1	$2K	Buy	+44	New	+$1.79K	﹤0.01%	882

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Front Row Advisors's XPH Position: Q2 2026 in Review

Front Row Advisors held its State Street SPDR S&P Pharmaceuticals ETF (XPH) position steady in Q2 2026 at 18 shares worth $1.26K. The position accounts for ﹤0.01% of the portfolio, ranked #527.

Front Row Advisors first reported a position in XPH in Q1 2019 and has held it in 29 quarters since. The position peaked at $2K in Q3 2024. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

Front Row Advisors held 18 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.26K as of Q2 2026.
Front Row Advisors left its State Street SPDR S&P Pharmaceuticals ETF share count unchanged in Q2 2026.
State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #527 holding.
Front Row Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2019 and has held it in 29 quarters since.
Front Row Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2K in Q3 2024.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.